top of page

Price

chg

chg neg

quotes and stock data may be delayed 15 minutes

 My Notes

Only BPIQ Pro members can create company notes. Learn more here.

52 wk low

low api

52 wk hi

high api

Cash

$505.6 M

Burn Rate (Qtr)

$21.0 M

Mkt Cap

mkt cap api

Avg Volume

volume api

*cash/burn updated:

Q1 '22

Drug Pipeline

Click the button to see the updated pipeline

No drug found

We don't have any drug data for this company yet

Drug | Disease (links)

Stage (next event)

Catalyst Date

Drug Name

Indication

Phase

Event

Exp Date

A free account is required to see the catalyst dates, notes, and more!

Loading Catalysts...

search in progress

Pipeline powered by

ANAB

BPIQ_Logo_RGB-01.jpg

Company Profile

AnaptysBio is a clinical-stage biotechnology company developing first-in-class immunology therapeutic product candidates to patients. We are focused on emerging immune control mechanisms applicable to inflammation and immuno-oncology indications.

Recent Posts

See what the community is saying - click to see full post.

#AACR24: Hedge Funds Hold These Cancer Companies

Amp Company Coverage And Ratings

How Did Q1 Hedge Fund Top 20 Returns Compare to Other Quarters?

ANAB - Amp's Current Rating and Updated Positions

ANAB - Amp's Current Rating and Updated Positions

Q1 '22 EcoR1 Top 10 Holdings (hedge fund)

bottom of page